Skip to Main Content

Paper Details

Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.
Neuro Oncol
3
2023
CpG, CpG sites, DNA, Docetaxel, Meningioma, cancer, double-stranded DNA, meningioma, meningioma cell sources, meningioma cells, meningiomas, mice, patient, patient-derived meningioma cell lines, primary intracranial tumor, tumor, tumors
Author NameAffiliation
Mark W YoungbloodFeinberg School of Medicine, Northwestern University
Mark W YoungbloodNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Stephen T MagillFeinberg School of Medicine, Northwestern University
Stephen T MagillNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Stephen T MagillFeinberg School of Medicine, Northwestern University
Stephen T MagillNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Dusten UnruhFeinberg School of Medicine, Northwestern University
Dusten UnruhNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Kathleen McCortneyFeinberg School of Medicine, Northwestern University
Kathleen McCortneyNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Felix SahmUniversity of Heidelberg and DKFZ
Felix SahmUniversity of Heidelberg and DKFZ
Kenneth AldapeCenter for Cancer Research, National Cancer Institute
Kenneth AldapeCenter for Cancer Research, National Cancer Institute
Amy B HeimbergerFeinberg School of Medicine, Northwestern University
Amy B HeimbergerNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Craig HorbinskiFeinberg School of Medicine, Northwestern University
Craig HorbinskiNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Craig HorbinskiFeinberg School of Medicine, Northwestern University
  • 1 - 19

Datasets

Release 1.2